Press Release

Sysmex Establishes New Measurement Technology that Achieves Even Higher Sensitivity for Its HISCL®-Series Immunochemistry Testing Analyzers

  Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has established a new, highly sensitive measurement technology for its products in the immunochemistry testing field.

  As a way of measuring proteins in the blood, immunochemistry testing has a wide range of applications, from the diagnosis of infectious diseases, cancers and heart diseases to their courses of treatment. As such, immunochemistry testing plays an essential role in the early detection of diseases and determination of therapeutic effects.

  To date, Sysmex has launched the HISCL-5000 and HISCL-2000i fully-automated immunoassay analyzers, which employ chemiluminescence enzyme immunoassay methodology, and these instruments have been introduced primarily at medical institutions in Japan. Sysmex also augmented its lineup in September, 2014 with the addition of the HISCL-800, a compact analyzer for immunochemistry testing.

  In the area of immunochemistry testing, the Company has now combined the immune complex transfer method1 with a chemiluminescent enzyme-linked immune reaction to establish a new, highly sensitive measurement technology that can be used for measurement by the HISCL-Series.
  The new technology enables measurement of HBs antigen—one immunochemistry testing parameter—with a sensitivity approximately 60 times higher than Sysmex’s conventional technology. By consequently enabling the highly sensitive detection of minute quantities of proteins that previously could not be determined, the technology is expected to generate new clinical value for immunochemistry testing parameters.

  We intend to put this technology to practical use by incorporating it into the HISCL-Series and aim to enhance the liquid biopsy2 capabilities of our in vitro diagnostic technology platform. 

  Going forward, Sysmex will continue to pursue a variety of innovative technological developments, including the development of even more highly sensitive protein measurement technologies. In addition, the Company is pursuing biomarker acquisition through open innovation in collaboration with research institutions and medical facilities. In these ways, we aim to contribute to the advancement of healthcare, such as through the realization of personalized medicine.

1 Immune complex transfer method:
After the immune complex (products of the antigen-antibody reaction) included on the object to be measured is formed onto beads or other carriers, the complex is disassociated from the surface of the carrier while retaining its shape. Next, the disassociated immune complex is captured by another carrier and measured. This approach curtails the adsorption of unnecessary proteins onto the carrier and the background signal that this causes, allowing highly sensitive measurement.


2 Liquid biopsy:
Detection of cancer or other diseases by testing blood or other bodily fluids. This type of testing is less invasive than conventional physical biopsies.
  • Information contained in the press release is current as of the date of the announcement,
    but may be subject to change without prior notice.

Back to "Press Release"